Longitudinal changes in forced expiratory volume in 1 s in patients with eosinophilic chronic obstructive pulmonary disease

被引:2
|
作者
Jo, Yong Suk [1 ]
Moon, Ji-Yong [2 ]
Park, Yong Bum [3 ]
Kim, Yee Hyung [4 ]
Um, Soo-Jung [5 ]
Kim, Woo Jin [6 ,7 ]
Yoon, Hyoung Kyu [8 ]
Ha Yoo, Kwang [9 ]
Jung, Ki-Suck [10 ]
Rhee, Chin Kook [1 ]
机构
[1] Catholic Univ Korea, Dept Internal Med, Div Pulm & Crit Care Med, Seoul St Marys Hosp,Coll Med, 222 Banpo Daero, Seoul 06591, South Korea
[2] Hanyang Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[3] Hallym Univ, Kangdong Sacred Heart Hosp, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Seoul, South Korea
[4] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Sch Med, Dept Pulm Allergy & Crit Care Med, Seoul, South Korea
[5] Dong A Univ, Coll Med, Dept Internal Med, Div Resp Med,Med Ctr, Busan, South Korea
[6] Kangwon Natl Univ Hosp, Dept Internal Med, Chunchon, South Korea
[7] Kangwon Natl Univ Hosp, Environm Hlth Ctr, Chunchon, South Korea
[8] Catholic Univ Korea, Dept Internal Med, Div Pulm & Crit Care Med, Yeouido St Marys Hosp,Coll Med, Seoul, South Korea
[9] Konkuk Univ, Sch Med, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Seoul, South Korea
[10] Hallym Univ, Sacred Heart Hosp, Dept Pulm Allergy & Crit Care Med, Anyang, South Korea
关键词
COPD; Blood eosinophil count; Exacerbation; Forced expiratory volume in 1 s; Longitudinal change; SHORT-TERM RESPONSE; POST-HOC ANALYSIS; INHALED CORTICOSTEROIDS; BLOOD EOSINOPHILS; EXTRAFINE BECLOMETHASONE/FORMOTEROL; SPUTUM-EOSINOPHILIA; COPD; EXACERBATIONS; INFLAMMATION; DECLINE;
D O I
10.1186/s12890-022-01873-8
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Data on changes in lung function in eosinophilic chronic obstructive pulmonary disease (COPD) are limited. We investigated the longitudinal changes in forced expiratory volume in 1 s (FEV1) and effects of inhaled corticosteroid (ICS) in Korean COPD patients. Methods Stable COPD patients in the Korean COPD subgroup study (KOCOSS) cohort, aged 40 years or older, were included and classified as eosinophilic and non-eosinophilic COPD based on blood counts of eosinophils (greater or lesser than 300 cells/mu L). FEV1 changes were analyzed over a 3-year follow-up period. Results Of 627 patients who underwent spirometry at least twice during the follow up, 150 and 477 patients were classified as eosinophilic and non-eosinophilic, respectively. ICS-containing inhalers were prescribed to 40% of the patients in each group. Exacerbations were more frequent in the eosinophilic group (adjusted odds ratio: 1.49; 95% confidence interval: 1.10-2.03). An accelerated FEV1 decline was observed in the non-eosinophilic group (adjusted annual rate of FEV1 change: - 12.2 mL/y and - 19.4 mL/y for eosinophilic and non-eosinophilic groups, respectively). In eosinophilic COPD, the adjusted rate of annual FEV1 decline was not significant regardless of ICS therapy, but the decline rate was greater in ICS users (- 19.2 mL/y and - 4.5 mL/y, with and without ICS therapy, respectively). Conclusions The annual rate of decline in FEV1 was favorable in eosinophilic COPD compared to non-eosinophilic COPD, and ICS therapy had no beneficial effects on changes in FEV1.
引用
收藏
页数:8
相关论文
共 50 条